Clinical TrialSep 4, 2026, 05:27 PM
Novartis Pelacarsen Trial Fails Primary Endpoint for Cardiovascular Events
AI Summary
Novartis AG announced that its Phase III Lp(a)HORIZON trial for pelacarsen, a treatment for elevated Lp(a) and cardiovascular disease, did not meet its primary endpoint. The trial, which involved over 8,000 patients, aimed to reduce the risk of cardiovascular events compared to placebo. While pelacarsen successfully lowered Lp(a) levels, it did not demonstrate a significant reduction in cardiovascular events in the overall study population. The company stated that the findings provide important scientific understanding and will be presented at an upcoming medical congress. Novartis holds global rights to pelacarsen through an agreement with Ionis Pharmaceuticals.
Key Highlights
- Novartis' pelacarsen Phase III Lp(a)HORIZON trial did not meet its primary endpoint of reducing cardiovascular events compared to placebo.
- The trial evaluated pelacarsen in 8,323 patients with elevated Lp(a) and established cardiovascular disease.
- Lower lipoprotein (a) levels were achieved with pelacarsen, but this did not translate to reduced cardiovascular risk in the overall study population.
- The findings provide new evidence on the relationship between Lp(a) lowering and cardiovascular outcomes.
- Novartis obtained global rights to pelacarsen from Ionis Pharmaceuticals.
Price Impact
More from NVS